$41.3 million. That is what the US federal government has obligated so far to one company, Verily, to run wastewater testing for the Centers for Disease Control and Prevention. The contract, a definitive agreement now in its final months, funds a quiet infrastructure project that began as a pandemic scramble and is turning into something permanent.
Wastewater surveillance has moved from an emergency COVID-era tool to contracted national infrastructure, with the CDC's main testing contract now held by Alphabet's Verily after a prior run by Biobot Analytics.
The economics have shifted from outbreak response to standing capacity: verifiable federal spending, multi-year contracts, and a growing list of pathogens tested from the same samples.
The real question for investors is not who holds today's contract. It is whether wastewater genomics becomes a durable utility business, or a policy-dependent program that contracts when the threat headlines fade.
Federal wastewater surveillance contract
Obligated amount on the CDC wastewater testing contract held by Verily Life Sciences, with roughly $38.1M already outlaid as the agreement approaches its current end date of August 2026. · USASpending.gov, 2026
Track the contract trail and a pattern emerges. The CDC launched its National Wastewater Surveillance System (NWSS) in September 2020 to monitor SARS-CoV-2 in sewage. Biobot Analytics, a Massachusetts Institute of Technology (MIT) research spin-off founded in 2017, won early work with the Department of Health and Human Services and then with the CDC itself. Its CDC contract ended on September 15, 2023. Eleven days later, on September 26, the agency awarded a new contract to Verily.
The CDC's own program page, updated July 31, 2026, still describes the national wastewater testing contract as "currently with Verily Life Sciences, LLC." Data from the previous arrangement is labeled under the "Biobot_Analytics" source. The transition is complete, and the public record shows why the handoff matters: it now tests samples from up to 400 participating treatment plants for SARS-CoV-2, mpox virus, and other pathogen nucleic acids under the contract.
NWSS testing footprint
Up to 400 participating wastewater treatment plants served under the flexible testing contract with the CDC's National Wastewater Surveillance System. · GenomeWeb, 2023
From emergency response to standing capacity
The pandemic forced a decade of wastewater epidemiology into months. In 2020, the field had a sparsely funded history and a handful of academic labs. By 2021, the US federal government was directing more than $100 million a year at it, and commercial genomics vendors were launching dedicated wastewater kits. The question everyone deferred was what happens when the emergency ends.
The Verily contract is the answer taking shape. Under its terms, Verily's laboratories provide participating NWSS sites with testing services, and the firm brings its own stack: lab technicians, data scientists, and a platform built for real-time wastewater surveillance. It had already been running a project called WastewaterSCAN with Stanford and Emory universities, and that project had a notable early result. It detected the mpox virus in California wastewater using digital PCR before cases were identified through clinical testing, which let local public health direct testing, outreach, and vaccine resources more precisely.
That is the pitch in one sentence: wastewater sees an outbreak before clinics do. The CDC's Advanced Molecular Detection program makes the same point, noting that wastewater surveillance can show changing infection trends for SARS-CoV-2 an average of 4 to 6 days before the same changes show up in clinical cases.
Why the contract changed hands
The November 2023 handoff from Biobot to Verily was not a demotion of the field. It was a consolidation. The CDC expanded its wastewater surveillance targets to roughly two dozen pathogens, and serving 400 treatment plants with flexible, multi-pathogen testing favors a contractor with Alphabet-scale lab capacity behind it.
"Supporting the CDC and NWSS significantly extends Verily's footprint as a leading provider in real-time wastewater surveillance in the US and reinforces our vision of impacting public health worldwide."— Andrew Trister, Chief Scientific Officer, Verily, October 2023
For Biobot, the loss of the federal contract was a pivot point, not a stop sign. In July 2026, Massachusetts announced it was ending its own contract with Biobot for wastewater surveillance. The Boston Globe reported that while many state labs focus on monitoring a handful of pathogens, Biobot is investing in technologies capable of detecting thousands. The company is betting that breadth, not depth, is where the value is headed.
That divergence is the whole story in miniature. One contractor positions itself as the utility-scale operator: reliable, tested, integrated with national infrastructure. The other positions itself as the discovery engine: sample once, read a thousand signals, catch the pathogen nobody was looking for. Both cannot win the same contracts forever.
What the transfer says about wastewater economics
Confirmation criteria: a multi-year renewal or expansion of the current contract beyond August 2026, or a competing national award to another large operator.
What happens to the market a year from now?
Probability: 65%. Basis: the CDC contract structure, the Massachusetts decision, and the funding pattern of the last three years all point the same way, and no credible source suggests a return to pandemic-era ad-hoc spending.
✅ Arguments for the two-tier market
State and international buyers want broader detection than clinical surveillance provides, which rewards the discovery-engine model.
Sequencing costs keep falling, widening the addressable market for routine wastewater genomics.
Confirmation criteria: renewal of the current federal contract, a second large national award, or visible state-level procurement of multi-pathogen services.
❌ Arguments against
Detection breadth does not yet have a clear reimbursement path, leaving the discovery model dependent on government grants and contracts.
Municipal adoption is slow where sewer networks are fragmented or nonexistent.
Disconfirmation criteria: a multi-year federal funding cut, or state programs moving testing fully in-house.
The signals worth tracking
Contract status past August 2026: renewal, expansion, or rebid will define the utility-tier benchmark.
Biobot's multi-pathogen platform: whether state and sovereign buyers adopt thousand-pathogen detection at contract scale.
CDC target count: each expansion of NWSS testing targets increases the value of standing lab capacity.
New national awards in other countries, the same consolidation story playing out outside the US.
Development scenarios
🟢 Optimistic scenario (25%)
Implications: multiple durable private companies with contract-based revenue, and a visible institutional market for the underlying sequencing and assay technology.
🟡 Base-case scenario (55%)
Implications: a real but niche private market, with contract concentration risk for any single operator.
🔴 Pessimistic scenario (20%)
Implications: the field reverts to pre-2020 sparsity, and early investors in the space take the loss.